Logo

Ingenuity Licenses Pathway Analysis Software to NCI

Apr 12, 2005

NEW YORK, April 12 (GenomeWeb News) - The National Cancer Institute Center for Cancer Research has licensed pathway analysis software from Ingenuity systems, the Mountain View, Calif.-based company said today.

 

Under the agreement, all researchers at the NCI will have access to Ingenuity's Pathway Analysis software, which includes a curated database of protein, gene, cell, tissue, drug, and disease networks.

 

Ingenuity aims to gain a stronger foothold in the academic and government research world this year, CEO Jake Leschly said in a company statement.

Breaking News
The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.